Using MAPK synergies by co-targeting the AKT, MTOR, and PIK3CA has shown promise in other HNSCC studies.25,26 We also observe a statistically significant increase in AKT phosphorylation at 72 hours. This evidence concerns the gene MTOR and head and neck squamous cell carcinoma.